08:06 AM EDT, 10/25/2024 (MT Newswires) -- IDEAYA Biosciences ( IDYA ) reported "positive" interim expansion data Friday for IDE397 in patients with methylthioadenosine phosphorylase-deletion urothelial cancer and non-small cell lung cancer.

The oncology company said that it observed a "manageable safety profile" with no drug-related serious adverse events or discontinuations at the 30mg once-a-day expansion dose.

Shares of IDEAYA Biosciences ( IDYA ) were up nearly 7% in recent premarket activity.

Price: 31.20, Change: +2.00, Percent Change: +6.85